Dabrafenib Plus Trametinib May Be Effective Therapy for Thyroid Cancer

Share this content:
Patients with ATC have a very poor prognosis and are left with few systemic therapy options.
Patients with ATC have a very poor prognosis and are left with few systemic therapy options.

Dabrafenib plus trametinib is the first well-tolerated systemic treatment regimen to demonstrate clinical efficacy in patients with BRAFV600E-mutated anaplastic thyroid cancer (ATC), according to an article published in the Journal of Clinical Oncology.1

Patients with ATC have a very poor prognosis and are left with few systemic therapy options. For this cohort of a larger phase 2 study (ClinicalTrials.gov Identifier: NCT02034110), researchers analyzed the outcomes of 16 patients with BRAFV600E-mutated ATC and administered dabrafenib 150 mg twice daily and trametinib 2 mg once daily.

All enrolled patients previously received radiation therapy and/or surgery; 6 patients progressed after prior systemic therapy.

After a median follow-up of 47 weeks, the overall response rate was 69% (11 of 16; 95% CI, 41%-89%), and 7 patients have ongoing responses. Results for median duration of response, overall survival, and progression-free survival were not evaluable, but had 12-month estimates of 90%, 80%, and 79%, respectively.

The most frequently reported adverse events across all cohorts of the study included fatigue, pyrexia, and nausea.

The authors added that these “data indicate that tumor mutation screening should be performed for patients with ATC as it has the potential to transform outcomes for these patients.”

Reference

  1. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 2017 Oct 26. doi: 10.1200/JCO.2017.73.6785 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters